STAT’s Post

🚀 Biotech Q3 Scorecard: 19 Stock-Moving Events to Watch! 📊 Exciting times ahead in the biotech world! Here are key developments to keep on your radar: Alnylam Pharmaceuticals vutrisiran vs BridgeBio acoramidis for ATTR-CM: ESC presentation in August Novo Nordisk's monlunabant for obesity: Phase 2 results (watch Skye Bioscience Inc. and Corbus, LLC too!) Viridian Therapeutics, Inc.'s VRDN-001 for thyroid eye disease: Phase 3 readout in September Sage Therapeutics' Sage-324 for essential tremor: Mid-stage study results Apellis Pharmaceuticals' Empaveli for kidney diseases: Phase 3 VALIANT study results early Q3 Eli Lilly and Company's bimagrumab for obesity: Phase 2 results mid-year UCB and Biogen's dapirolizumab for lupus: Phase 3 results Neurocrine Biosciences's NBI-1117568 for schizophrenia: Phase 2 results Elevation Oncology's EO-3021 for gastric/pancreatic cancers: Data update Plus: • AstraZeneca's Imfinzi FDA panel (July 25) • Potential approvals for Alzheimer's drugs: Eisai US/Biogen's Leqembi (EU) • Multiple FDA decisions including Gilead Sciences, Regeneron, Syndax Pharmaceuticals, Roche, and Bristol Myers Squibb 🔬 The biotech sector is buzzing with potential breakthroughs. Which company or development are you most excited about? Share your thoughts below! 👇 #Biotech #PharmaTrends #ClinicalTrials #DrugDevelopment

Obesity and the associated comorbidities are getting more attention. Take time to read this paper on obesity related clinical research by two of my colleagues

📢Breakthrough Collaboration Targets $80bn Obesity Market 🗞️ British companies Arecor Therapeutics plc and TRX Biosciences Limited are partnering to develop an oral GLP-1 receptor agonist for obesity treatment. 🍔🍟 The collaboration aims to create an oral formulation with enhanced bioavailability, providing a more comfortable and convenient treatment option for patients. 💊 Currently, the obesity drug market is dominated by Novo Nordisk's semaglutide and Eli Lilly and Company tirzepatide. The partnership has the potential to target an $80bn market and expand into other peptide-based treatments. 💰💡 #BioprocessUpdates #ObesityTreatment #GLP1ReceptorAgonist #ArecorTherapeutics #TRxBiosciences #Collaboration #EnhancedBioavailability #ConvenientTreatment #NovoNordisk #Semaglutide #EliLilly #Tirzepatide #MarketExpansion #PeptideBasedTreatments #HealthcareInnovation #MedicalResearch ▷ Read the full article here: 📎 https://lnkd.in/drQAG5-U

🔬 Eli Lilly eyes MASH market expansion with promising Phase II tirzepatide readout. Here is my summary: 📰 Eli Lilly published promising clinical data on their Phase II MASH trial with tirzepatide, showing it improves liver fibrosis. This paves the way for a potential label expansion into metabolic dysfunction-associated steatohepatitis (MASH) as Lilly seeks further growth opportunities for tirzepatide, one of its best-selling weight-loss and obesity treatments. 🏆 The trial (n=190) met its primary endpoint: 51.8%, 62.8%, and 73.3% of participants receiving tirzepatide (5mg, 10mg, 15mg) showed no MASH with no fibrosis worsening, compared to 13.2% on placebo. The drug also improved body weight, liver injury markers, and biomarkers of fibrosis, inflammation, and liver fat. 👀 Following this latest readout, Madrigal Pharmaceuticals, which secured the first-ever MASH drug approval with Rezdiffra, had its shares fall by almost 9%. Another competitor in this space is Viking Therapeutics, with its experimental drug VK2809, which recently reported results from a Phase 2b trial showing statistically significant reductions in liver fat. #elililly #tirzepatide #zepbound #liver #trials #mash

Competitive Dynamics in Metabolic Disorder: Interesting Times to Witness The metabolic disorder landscape is undergoing a seismic shift, with recent FDA approvals igniting an intriguing competitive dynamic. In the last two weeks, Novo Nordisk's Wegovy received approval as a preventative for cardiovascular events in obese patients, while Madrigal's Rezdiffra secured the world's first approval for NASH with liver fibrosis. Although these approvals seem independent, a deeper analysis reveals the potential for intense competition between their underlying mechanisms. While Rezdiffra addresses a long-standing unmet need in NASH, it may face fierce competition from liver disease therapies and the increasingly prominent GLP-1 drug class. A Nature Reviews on Drug Discovery article highlights nearly 10 late-stage assets, including three GLP-1 analogs from Novo Nordisk, Lilly, and Boehringer Ingelheim/Zealand Pharma. Growing evidence suggests GLP-1 agonists exhibit anti-inflammatory effects on the liver, improving liver enzymes and potentially impacting fibrosis. A positive trial result could elevate GLP-1 agonists' competitive positioning, potentially relegating Rezdiffra to treating only advanced-stage patients. In this evolving landscape, Madrigal must invest in clinical trials to study Rezdiffra's preventive effect on NASH progression and associated fibrosis. Demonstrating efficacy in prevention could carve out a competitive advantage, solidifying Rezdiffra's position as a first-line therapy. As the battle for market share intensifies, the metabolic disorder arena will witness a captivating interplay of clinical data, strategic positioning, and commercial maneuvering. Pharmaceutical companies must stay agile, adapt to evolving dynamics, and leverage scientific expertise to differentiate offerings and secure a foothold in this rapidly evolving landscape. #MetabolicDisorders #NASH #LiverFibrosis #GLP1Agonists #CardiovascularRisk #ObesityTreatment #WeightLoss #DrugDevelopment #ClinicalTrials #CompetitiveStrategy #PharmaceuticalInnovation #MedicalBreakthroughs #HealthcareLandscape #FDAApprovals #BlockbusterDrugs #MarketCompetition #CommercialStrategy #BusinessIntelligence #TherapeuticAreaStrategy #ProductDifferentiation #StrategicPositioning #RegulatoryApprovals #PipelineAssets #LateStageAssets #PhaseIIITrials

🌍 Key Trends in Pharma R&D 🧪💊 This article highlights some key observations from the top pharmaceutical players in terms of R&D budgets and strategies for 2023. 🥇 Merck & Co. takes top spot with $30.53 billion R&D budget 🚀 Pfizer and AstraZeneca lead the pack in the number of R&D programs, emphasizing their focus on pipeline development and novel therapeutics. 🎯 Oncology, immunology, and neurology continue to be the prime focus, with obesity gaining traction. ✨ Advancements in antibody-drug conjugates (ADCs) make their mark in drug development. #drugdevelopment #pharma #ResearchAndDevelopment #R&D

Science's 2023 breakthrough goes to Glucagon like peptide-1 (GLP-1) agonists, not only because of the importance of the research but also their impacts across society. These new therapies are reshaping not only how obesity is treated, but how it’s understood—as a chronic illness with roots in biology, not failure of willpower. Read more: https://lnkd.in/ecvdfy9q #pharma, #peptides #glp1

📣 Calling all Obesity, Diabetes, NASH, and GLP-1 Specialists! ⏳ The $550 early registration discount for the GLP-1 Based Therapeutics Summit expires next Friday, 15th of March. This year we are thrilled to unite BioAge Labs, Eli Lilly, Novo Nordisk, Pfizer, Carmot Tx | Roche & more in Philadelphia to delve into key topics including: 🔍 Whether the observed benefits of GLP-1s for novel therapeutic avenues are attributable to weight reduction or other mechanisms? 🎯 Improving the targeting of GLP-1 weight loss and improving the body composition of elderly patients. 🌐 Assessing the potential impacts of the Inflation Reduction Act & future regulatory horizons on clinical progress & pricing to streamline speed to market. To read further, grab your copy of the full agenda here - https://ter.li/hh4tbx If you're eager to join KOLs for invaluable networking and discussions regarding advancements to GLP-1 commercial & clinical strategy, secure your spot here - https://ter.li/sa51av Or please feel free to email: oliver.smare@hansonwade.com #glp1 #obesity #type2diabetes #diabetes #cardiovasculardisease #fattyliverdisease #incretin #endocrinology

Catalyze a new era of drug development in metabolic syndrome: The 7th Obesity & NASH Drug Development Summit is back in Boston! Navigate end-to-end strategic updates in NASH & obesity amongst industry leaders that are sharing novel insights in utilising non-invasive biomarkers, developing 3D cell-based models and trialling combination therapies beyond GLP-1 RAs. Register by Friday and save $1,750 ⌛ View the full Event Guide here: https://ter.li/e3rmod Expert Speaker Faculty:  Ana Paula Cancino MD, MSc Brian Finan Cindy Hartsfield Dong-ki Lee Erik Tillman, PhD Feng Liu JoAnne Foody Jerry Colca Jen-Chieh(Jay) Chuang Jingye Zhou John Griffin Kathleen Elias PhD Kavita Juneja Kevin Hart Linh Vong Marc Thibonnier Marie O'Farrell Mark Hartman Mary E. Haas Michael Cooreman Michelle Long Mourad Topors, PhD Murielle Veniant, PhD. Noah Davidsohn Patrick Mayo Rebecca Taub Rhianna Laker Sara Toftegaard Hjuler Sarah Vargas Dr Sharat Varma Stan Watowich Sungjin Park Teo Uysal Tien Lee Todd Hobbs MD Vaidehi Joshi Wen-Wei Tsai Wladislaw [Vlad] Malkov Xinle Wu Zhao Wang, PhD, MS, MD Don’t miss out on this invaluable forum to overcome your regulatory and commercial hurdles, network with leading biopharma, understand the root cause of obesity and assimilate the recent wins in NASH drug development. #nash #obesity #obesitytreatment #metabolic #metabolichealth #metabolicdisease #semaglutide #therapy #liverdisease #fattyliver #fattyliverdisease

https://lnkd.in/gv3NPn3d Key Insights: • The Omega collaboration aims to utilize the company’s platform for the creation of an epigenomic controller, forming a novel approach to managing obesity •The Cellarity collaboration will expand on prior efforts and employ the company’s platform to develop a small molecule therapy for metabolic dysfunction-associated steatohepatitis (MASH) Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #novonordisk #collaboration #alliances #industry #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights